Clinical Trial Detail

NCT ID NCT02406521
Title Exploratory Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

renal cell carcinoma

Therapies

Pazopanib

Radium Ra 223 dichloride

Sorafenib

Age Groups: adult

No variant requirements are available.